Tag

East St Archives - Carey Danis & Lowe

Carey Danis & Lowe Represents Plaintiffs in Home Depot Data Breach Lawsuits

By | Consumer protection, Uncategorized

homedepotCarey Danis & Lowe is representing plaintiffs in a Home Depot data breach lawsuit in an East St. Louis federal court. The class action lawsuit involves a group of plaintiffs who claim that their personal information was stolen due to Home Depot’s faulty data security system.

Home Depot officially confirmed that a data breach had occurred on September 9, 2014.

Plaintiffs who have been negatively impacted by the Home Depot data breach argue that the company failed to meet data security standards, a failure that is the most likely cause for the devastating leak of personal information.

Have You Been Financially Harmed by the Home Depot Data Breach?

The consumer protection and class action attorneys at Carey Danis & Lowe want to know if you have been financially harmed by the Home Depot data breach.

Have your credit rating and financial well being been compromised?

If so, Carey Danis & Lowe encourages you to seek justice for Home Depot’s poor handling of your personal information. During a free initial case evaluation, one of our consumer protection attorneys can walk you through your legal options and compensation eligibility.

Share your story with Carey Danis & Lowe today by calling us at 800.721.2519, or by completing a confidential case evaluation request.

 

Pradaxa MDL News: Manufacturer Fined for Neglectful Document Handling

By | Pharmaceutical litigation, Pradaxa, Uncategorized

pradaxa_lawsuitIn a federal Illinois court, Boehringer Ingelheim has been fined $1 million for neglecting to retain documents pertinent to a multidistrict litigation (MDL). It is unclear if the German pharmaceutical company can be accused of destroying or withholding the Pradaxa documents.

The fine was brought down upon Boehringer Ingelheim in the U.S. District Court for the Southern District of Illinois in the Pradaxa MDL.

U.S. District Judge David Herndon, who handed the manufacturer of Pradaxa the fine, called Boehringer Ingelheim’s practices regarding document retention outrageously neglectful.

According to Bloomberg, there are approximately over 1,700 Pradaxa bleeding lawsuits pending in the federal Illinois court. Plaintiffs have filed Pradaxa lawsuits alleging incidences of excessive loss of blood. When these excessive bleeding episodes become uncontrollable, they may become fatal, resulting in what is called a bleed-out death.

A blood-thinning agent, Pradaxa is a drug used to prevent incidences of blood clots and stroke in patients with atrial fibrillation.

The Pradaxa MDL is In re: Pradaxa Products Liability Litigation MDL no. 2385, and is being heard in East St. Louis, Illinois.

In addition to the Pradaxa MDL in Illinois, individuals who believe that they have been injured by the use of Pradaxa have filed lawsuits targeted at Boehringer Ingelheim from coast to coast, in Delaware, Connecticut, and California. There are also Pradaxa bleeding lawsuits pending in state courts in Illinois.

National Law Firm Representing Pradaxa Victims

As a national law firm headquartered in St. Louis that provides legal counsel to victims of defective drugs, Carey Danis & Lowe Pradaxa attorneys are currently investigating Pradaxa cases. If you believe that your injuries are the result of Pradaxa use, explore your legal options with one of our Pradaxa attorneys at Carey Danis & Lowe today.

We also have a team of highly experienced nurses and medical experts who are available to listen closely to your concerns about Pradaxa as it concerns patient health and safety.

Share your Pradaxa story with Carey Danis & Lowe today. Call 800.721.2519, or submit a confidential personal injury claim form.

Pradaxa MDL News: Court Convened for Status Conference in Early February

By | Pharmaceutical litigation, Pradaxa, Uncategorized

pradaxa4The Pradaxa multi-district litigation (MDL) met in early February for a status conference to discuss recent progress made in the discovery and deposition processes. According to Seth A. Katz, one of the lawyers representing the plaintiffs in the Pradaxa MDL, Boehringer Ingelheim Pharmaceuticals Inc. has not been meeting production deadlines.

According to the Pradaxa MDL status conference minutes, the plaintiffs asked for certain documents to be produced by Boehringer Ingelheim, the pharmaceutical company that develops and manufactures Pradaxa, an anticoagulant medicine prescribed to patients with non-valvular atrial fibrillation.

These document requests were made in late December and in mid-January. As of yet, these documents have been provided to neither the plaintiffs nor their legal counsel. Since then, the plaintiffs have voiced concern about whether Boehringer Ingelheim will transmit these custodial files to the plaintiffs for review.

The discovery phase in the Pradaxa MDL is important for the plaintiffs and their legal counsel in that it allows them to review the documents provided by Boehringer Ingelheim, and in doing so, build a case around the evidence presented in these internal documents.

To date, approximately 258 cases have been consolidated into the Pradaxa MDL. These consolidated cases are being heard in the U.S. District Court for the Southern District of Illinois. The Pradaxa MDL is known as in Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation MDL no. 2385. Chief Judge David R. Herndon is presiding over court proceedings.

The court minutes state that the next status conference in the Pradaxa MDL has been scheduled for March 14.

Pradaxa has gained a reputation for causing serious bleeding events that can be fatal. Patients with atrial fibrillation have used Pradaxa to prevent stroke and blood clots. However, Pradaxa has not worked as designed, and has led to a severe bleeding events and numerous deaths.

Boehringer Ingelheim’s anticoagulant medicine was intended to replace warfarin, a drug introduced in the 1950s. Pradaxa has proved to be an insufficient replacement, if it can even be considered a replacement.

An enormous complication with the use of Pradaxa is that it does not have a reversal agent, meaning a medicine that can be ingested to reverse the blood thinning properties present in Pradaxa. Unlike warfarin, Boehringer Ingelheim released Pradaxa onto the market without a panacea for serious bleeding events. The reversal agent for warfarin is Vitamin K.

The defective drug and Pradaxa lawyers at Carey Danis & Lowe continue to follow the Pradaxa MDL in East St. Louis for any updates that may benefit our Pradaxa clients. Carey Danis & Lowe is accepting Pradaxa claims, and offering free legal consultations about Pradaxa cases.

If you or someone you love has been injured by Pradaxa, you and your loved one may be eligible to receive compensation. To file a Pradaxa lawsuit, contact a Pradaxa lawyer at Carey Danis & Lowe today by calling 800.721.2519 or submit a legal claim form.

Carey Danis & Lowe Issues an Update on the Pradaxa Multi-District Litigation No. 2385

By | Pharmaceutical litigation, Pradaxa, Uncategorized

Published December 27, 2012 by PR Web

St. Louis, MO (PRWEB) December 27, 2012

Carey Danis & Lowe Issues an Update on the Pradaxa Multi-District Litigation No. 2385Pradaxa lawsuits have been consolidated into a Multi-District Litigation being heard in the U.S. District Court, Southern District of Illinois. The Pradaxa MDL has been named Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation. The last Pradaxa MDL meeting occurred on Thursday, December 13, 2012, where Plaintiffs’ representatives as well as the Defendants’ legal counsel convened for a Status Conference.

The MDL No. 2385 is presided over by Chief Judge David R. Herndon in East St. Louis, Illinois. The MDL is currently in the pre-trial discovery phase.

As outlined in the court’s minutes, both sides have been working to approve the First and Second Sets of Discovery gathered by the Plaintiffs legal representatives. Though the two side came to a written agreement on the Second Set of Discovery, in regards to the First, the Plaintiffs’ legal representatives have been working “to resolve pending disputes.”

According to the Pradaxa MDL 2835 Status Conference minutes from December 13, the Plaintiffs’ First Set of Discovery has resulted in a number of unsettled disagreements between the Plaintiffs Lead Counsel and Boehringer Ingelheim Pharmaceuticals, Inc. As court documents detail, Boehringer Ingelheim has objections with regard to the Plaintiffs Lead Counsel’s First Set of Discovery.

As a result of the yet unresolved issues with the First Set of Discovery, Boehringer Ingelheim is filing a protective order, and plans to do so by December 21, 2012. In response to the protective order and in an effort to acquire vital evidence and documents, the Plaintiffs Lead Counsel plans to file a responsive pleading early next year.

Currently, over 170 plaintiffs have a case that has been consolidated into MDL No. 2385. These plaintiffs claim that the ingestion of Pradaxa led to serious Pradaxa-related injuries including excessive bleeding, uncontrollable bleeding, and fatal bleed-outs. Furthermore, these Pradaxa lawsuits claim that Boehringer Ingelheim neglected to warn healthcare providers and patients about the risks of using Pradaxa.

In addition, plaintiffs accuse Boehringer Ingelheim of further negligence in light of Pradaxa’s release onto the market without the simultaneous release of a reversal agent which is vital in treating excessive bleeding. Unlike warfarin which is counteracted by Vitamin K in excessive bleeding episodes, Pradaxa has no known panacea or reversal agent to control excessive bleeding.

Attorneys at Carey Danis & Lowe are currently seeking claims from individuals who have experienced a Pradaxa injury, including those listed above, such as excessive and uncontrollable bleeding events. For more information about filing a Pradaxa lawsuit, contact a defective drug lawyer at Carey Danis & Lowe at 800-721-2519.

Pradaxa Lawsuit News: Pradaxa MDL Convened in District Court in Illinois for Status Conference on January 14, 2013

By | Pharmaceutical litigation, Pradaxa, Uncategorized

Pradaxa Lawsuit News: Pradaxa MDL Convened in District Court in Illinois for Status Conference on January 14, 2013Court convened in the Pradaxa Multi-District Litigation (MDL) known as In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation) MDL No. 2385 for a Status Conference on January 14, 2013. The Pradaxa MDL is being heard in the U.S. District Court for the Southern District of Illinois in East St. Louis, and is being presided over by Chief Judge David R. Herndon.

An attorney on the Plaintiffs’ Co-Lead Counsel, Roger C. Denton, delivered an update on the development of a Privilege Log, a document listing items to be withheld during legal proceedings. Both parties have come to an agreement on what items to list on the Privilege Log as well as when Boehringer Ingelheim is scheduled to begin delivering items for the Privilege Log to the plaintiffs’ counsel.

Boehringer Ingelheim’s lawyers supplied an update on defense witness depositions, which have been scheduled for March. According to the Pradaxa MDL Status Conference minutes, both parties are working on scheduling these depositions, but have come across obstacles in determining deposition locations.

To date, there are 183 cases that have been consolidated into the Pradaxa MDL in East St. Louis, Illinois.

Pradaxa is an anticoagulant drug prescribed to patients with non-valvular atrial fibrillation. As an anticoagulant medication, Pradaxa was developed by Boehringer Ingelheim Pharmaceuticals, Inc. with the expectation that the drug would be a superior alternative to warfarin, an anticoagulant drug introduced in the 1950s.

Upon authorizing approval of the drug Pradaxa in October 2010, the U.S. Food and Drug Administration (FDA) began receiving adverse event reports, and more specifically, patient reports detailing episodes of severe and uncontrollable bleeding linked to the use of Pradaxa. As a result of these serious bleeding risk reports, the FDA continues to research the health risks of ingesting Pradaxa in the prevention of strokes and blood clots in patients with atrial fibrillation.

Lawyers at Carey Danis & Lowe are currently accepting Pradaxa claims, and are working on evaluating each Pradaxa lawsuit for inclusion in the MDL in East St. Louis, Illinois. If you or someone you love has suffered a severe bleeding event while taking Pradaxa, you and your loved one may be eligible to receive recompense for such undue suffering.

To submit a Pradaxa claim and for a free legal consultation regarding your Pradaxa case, contact an experienced trial lawyer at Carey Danis & Lowe by calling 800.721.2519.

Pradaxa Bleed-Out Deaths Surpass 500 in the United States

By | Pharmaceutical litigation, Pradaxa, Uncategorized

Pradaxa Bleed-Out Deaths Surpass 500 in the United StatesThough the drug manufacturer denies Pradaxa as a defective drug, the surmounting Pradaxa bleeding deaths, injuries, and lawsuits prove otherwise. Pradaxa was introduced onto the U.S. drug market in October 2010, after receiving approval by the U.S. Food and Drug Administration (FDA). The drug is manufactured by German pharmaceutical giant, Boehringer Ingelheim.

As a blood thinning medication, Pradaxa is used to prevent strokes and blood clots in patients suffering from atrial fibrillation.

However, one the complications identified with blood thinning medications is the risk of excessive internal bleeding. With other blood thinning drugs, such as warfarin, the reversal agent is vitamin K, which acts as a cure fore excessive bleeding.

However, with Pradaxa, when patients experience an episode of excessive and uncontrollable bleeding, there is no known cure to reverse or control the effects of Pradaxa. These severe bleeding episodes often result in what is called a Pradaxa bleed-out death.

Since its introduction two years ago, there have been reports of 500 deaths in the United States alone that are closely tied to Pradaxa.

With many patients in an uproar over the complications and deaths linked to Pradaxa, there are now over 150 lawsuits filed against Boehringer Ingelheim claiming that the drug company knew about the risk of Pradaxa bleeding deaths, but failed to provide this information to the FDA during the approval period.

Most of the Pradaxa lawsuits filed against the manufacturer have been issued in Southern Illinois. Pradaxa lawsuits have been consolidated into U.S. District Court, Southern District of Illinois in East St. Louis in Re: Pradaxa Products Liability Litigation, 12-MD-2385, overseen by U.S. District Judge David Herndon.

In speaking with Bloomberg News, a spokesperson for Boehringer Ingelheim, Emily Baier, stated that, “Boehringer Ingelheim believes that the product liability lawsuits filed against the company regarding Pradaxa are without merit.” Clearly, Pradaxa’s manufacturer is choosing to ignore the reality that Pradaxa has been linked to 500 deaths and over 3,000 side effect injuries in only 2 years of the drug being on the market.

Pradaxa was intended to be a replacement for warfarin, a drug approved by the FDA in June 1954. Warfarin is notorious for requiring numerous doctor’s visits and constant monitoring. Pradaxa was developed in an effort to cut down on these monitoring requirements. As Pradaxa deaths, patient complication reports, and mounting lawsuits indicate, the expectation of Pradaxa to revolutionize the blood thinning drug market has not been the reality.

If you or a loved one has fallen victim to the harmful side effects of Pradaxa, you may be entitled to receive compensation for your emotional, physical, and financial suffering. In cases where drug companies have clearly neglected to inform the public about the safety of their products, experienced defective drug lawyers at Carey Danis & Lowe believe it is our duty to work with clients in holding these drug manufacturers responsible for their gross negligence.

For a free legal consultation regarding your Pradaxa case, contact a Pradaxa lawyer at Carey Danis & Lowe today at 800.721.2519.